MINNEAPOLIS--(BUSINESS WIRE)--Vascular Solutions, Inc. (Nasdaq: VASC) today reported financial results for the fourth quarter and year ended December 31, 2010. Net revenue for the fourth quarter was $20.9 million, an increase of 15% from the fourth quarter of 2009, and a sequential increase of 5% from the third quarter of 2010. For the year ended December 31, 2010, net revenue increased by 15% to a record $78.4 million, representing the seventh consecutive year of greater than 10% revenue growth for Vascular Solutions.
Operating income for the fourth quarter was $3.4 million, a 54% increase over the fourth quarter of 2009. Net income of $15.0 million ($0.87 per diluted share) in the fourth quarter included $12.9 million ($0.75 per diluted share) of income tax benefit primarily resulting from the recognition of net operating loss carryforwards as a deferred tax asset. Not including the income tax benefit, earnings per share increased 30% to $0.12 per diluted share in the fourth quarter of 2010 from the fourth quarter of 2009. Both net revenue and net income for the fourth quarter were within guidance previously provided by the company.
Gross margin across all product lines was 65.8% in the fourth quarter of 2010, up from 64.9% in the fourth quarter of 2009 as the result of a continued shift in selling mix to higher margin products.
Commenting on the results, Vascular Solutions’ Chief Executive Officer Howard Root stated: “The fourth quarter completed another very successful year for Vascular Solutions. The clinical and financial success of our internal product development system was evident in our GuideLiner® catheter, which surpassed all our expectations in 2010. The benefit of our overall business plan was evident in our ability to continue to post double-digit percentage sales growth while several of our products reached the mature stage. And the benefit of our strong financial position was evident in the three accretive cash acquisitions that we completed over the last 12 months. With a full pipeline of internally-generated new products in development and additional acquisition and product distribution candidates in evaluation, we are very optimistic about our ability to continue with our consistent sales growth and success in 2011 and beyond.”
Fourth Quarter Net Revenue by Product Line
Net sales of catheter products were $12.0 million in the fourth quarter, an increase of 41% over the fourth quarter of 2009. “Sales of our GuideLiner catheter increased 43% sequentially from the third quarter, and the physician response to the GuideLiner continues to be outstanding. Based on the responses we’ve received and the expanded market potential we observe, we project sales of the GuideLiner will approximately double in 2011 from 2010. Sales of our Pronto® catheters increased 15% in the fourth quarter from the fourth quarter of 2009. With the new V4 version of the Pronto catheters FDA-cleared in December and initial clinical evaluations successfully completed in January, we expect sales of the Pronto line to continue to increase by greater than 10% in 2011. Adding to this organic sales growth in our catheter products, in the fourth quarter we benefited from $752,000 in sales of the SmartNeedle® products that we acquired in April 2010. Acquisitions will continue to benefit our catheter product sales in 2011 with the addition of our recently-acquired Guardian® valve and Elite™ snare products,” Mr. Root stated.
Net sales of hemostat products (primarily consisting of the D-Stat® Dry, D-Stat Flowable and D-Stat Radial products) were $5.9 million in the fourth quarter, a decrease of 1% from the fourth quarter of 2009. “Our market leading position with the D-Stat Dry in the patch market, a market that is not experiencing significant growth, puts us in a mature position with this category. However, with a new anti-microbial version of the D-Stat Dry expected to launch in the first half of 2011 and the new Hunter™ biopsy product already launched in Europe and expected to launch in the U.S. in the middle of 2011, we believe we have the ability to provide single-digit percentage growth in the hemostat product category in 2011,” commented Mr. Root.
Net sales of vein products (primarily consisting of the Vari-Lase® laser console and kits) were $2.8 million in the fourth quarter, a decrease of 14% from the fourth quarter of 2009. “The varicose vein market is unsettled, with several of our laser competitors engaged in severe price competition while they deal with an unfavorable jury verdict they received in their patent litigation in the fourth quarter, an issue that we settled back in 2008. With our Vari-Lase business now free of litigation, we intend to work to maintain our position in the market and expand as our laser competitors adjust to the legal verdict,” commented Mr. Root.
Financial Guidance
The Company projects net revenue to increase by approximately 15% to between $89 million and $91 million in 2011. Net income is projected to be between $0.50 and $0.54 per fully diluted share, an increase of 45% from a corresponding $0.37 per share in 2010 (not including $12.9 million ($0.76 per share) income tax benefit in the fourth quarter of 2010 and $3.5 million ($0.13 per share) litigation gain in the first quarter of 2010). Included in the net income projection for 2011 are $2.2 million in non-cash stock-based compensation and $0.8 million in amortization of intangibles, with an assumed 38% income tax rate.
For the first quarter of 2011, the Company projects net revenue to increase by 16% over the first quarter of 2010 to between $20.9 million and $21.3 million. Net income is projected to be between $0.08 and $0.10 per fully diluted share, compared to $0.08 per share in the first quarter of 2010 (not including $3.5 million ($0.13 per share) litigation gain in the first quarter of 2010). Included in the net income projection for the first quarter of 2011 are $0.6 million in non-cash stock-based compensation and $0.2 million in amortization of intangibles, with an assumed 38% income tax rate.
Conference Call & Webcast Information
Vascular Solutions will host a live webcast starting at 3:30 p.m., Central Time today to discuss the information contained in this press release. The live web cast may be accessed on the investor relations portion of the company’s web site at www.vascularsolutions.com. An audio replay of the call will be available until Tuesday, February 8, 2011 by dialing 1-888-203-1112 and entering conference ID# 3374312. A recording of the call will also be archived on the Company’s web site, www.vascularsolutions.com until Tuesday, February 8, 2011. During the conference call the Company may answer one or more questions concerning business and financial developments and trends, the Company’s view on earnings forecasts and new product development and financial matters affecting the Company, some of the responses to which may contain information that has not been previously disclosed.
| VASCULAR SOLUTIONS, INC. | |||||||||||||||||||||||||
| CONDENSED STATEMENTS OF OPERATIONS | |||||||||||||||||||||||||
| (In thousands, except per share data) | |||||||||||||||||||||||||
| Three Months Ended | Twelve Months Ended | ||||||||||||||||||||||||
| December 31, | December 31, | ||||||||||||||||||||||||
| 2010 | 2009 | 2010 | 2009 | ||||||||||||||||||||||
| (unaudited) | (note) | ||||||||||||||||||||||||
| Revenue: | |||||||||||||||||||||||||
| Product revenue | $ | 20,664 | $ | 17,712 | $ | 77,419 | $ | 66,726 | |||||||||||||||||
| License and collaboration revenue | 213 | 510 | 1,024 | 1,701 | |||||||||||||||||||||
| Total revenue | 20,877 | 18,222 | 78,443 | 68,427 | |||||||||||||||||||||
| Product costs and operating | |||||||||||||||||||||||||
| expenses: | |||||||||||||||||||||||||
| Cost of goods sold | 7,076 | 6,219 | 26,465 | 22,917 | |||||||||||||||||||||
| Collaboration expenses | - | 295 | 175 | 850 | |||||||||||||||||||||
| Research and development | 2,330 | 2,140 | 9,524 | 7,847 | |||||||||||||||||||||
| Clinical and regulatory | 990 | 794 | 3,551 | 2,886 | |||||||||||||||||||||
| Sales and marketing | 5,747 | 5,366 | 23,188 | 21,206 | |||||||||||||||||||||
| General and administrative | 1,145 | 1,180 | 5,183 | 4,555 | |||||||||||||||||||||
| Litigation | - | - | (3,529 | ) | - | ||||||||||||||||||||
| Amortization | 156 | - | 304 | - | |||||||||||||||||||||
| Operating income | 3,433 | 2,228 | 13,582 | 8,166 | |||||||||||||||||||||
| Interest expense | (5 | ) | (9 | ) | (20 | ) | (38 | ) | |||||||||||||||||
| Interest income | 8 | 5 | 38 | 48 | |||||||||||||||||||||
| Foreign exchange loss | (25 | ) | (8 | ) | (42 | ) | (10 | ) | |||||||||||||||||
| Income before tax | 3,411 | 2,216 | 13,558 | 8,166 | |||||||||||||||||||||
| Income tax expense | 11,561 | (593 | ) | 7,819 | (2,788 | ) | |||||||||||||||||||
| Net income | $ | 14,972 | $ | 1,623 | $ | 21,377 | $ | 5,378 | |||||||||||||||||
| Net income per share - basic | $ | 0.90 | $ | 0.10 | $ | 1.30 | $ | 0.34 | |||||||||||||||||
| Weighted average shares used in | |||||||||||||||||||||||||
| calculating - basic | 16,566 | 16,217 | 16,478 | 16,047 | |||||||||||||||||||||
| Net income per share - diluted | $ | 0.87 | $ | 0.10 | $ | 1.26 | $ | 0.33 | |||||||||||||||||
| Weighted average shares used in | |||||||||||||||||||||||||
| calculating - diluted | 17,138 | 16,680 | 17,008 | 16,475 | |||||||||||||||||||||
Note: Derived from the audited financial statements at that date.
| VASCULAR SOLUTIONS, INC. | ||||||||||
| CONDENSED BALANCE SHEETS | ||||||||||
|
December 31, |
December 31, |
|||||||||
|
2010 |
2009 |
|||||||||
|
(note) |
(note) |
|||||||||
| ASSETS | ||||||||||
| Current assets: | ||||||||||
| Cash and cash equivalents | $ | 17,360 | $ | 17,794 | ||||||
| Accounts receivable, net | 11,055 | 9,143 | ||||||||
| Inventories | 12,601 | 8,977 | ||||||||
| Prepaid expenses | 1,760 | 1,520 | ||||||||
| Current portion of deferred tax assets | 6,000 | 4,500 | ||||||||
| Total current assets | 48,776 | 41,934 | ||||||||
| Property and equipment, net | 5,320 | 3,793 | ||||||||
| Goodwill | 5,825 | 193 | ||||||||
| Intangible assets, net | 6,146 | - | ||||||||
| Deferred tax assets, net of current portion and liabilities | 12,390 | 5,835 | ||||||||
| Total assets | $ | 78,457 | $ | 51,755 | ||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||
| Current liabilities: | ||||||||||
| Total current liabilities | $ | 9,849 | $ | 6,789 | ||||||
| Long-term deferred revenue and contingent consideration, net | ||||||||||
| of current portion | 4,505 | 4,567 | ||||||||
| Shareholders’ equity: | ||||||||||
|
Total shareholders’ equity |
64,103 | 40,399 | ||||||||
| Total liabilities and shareholders’ equity | $ | 78,457 | $ | 51,755 | ||||||
Note: Derived from the audited financial statements at that date.
| VASCULAR SOLUTIONS, INC. | |||||||||||||||||||||||||
| SUPPLEMENTARY OPERATIONS DATA | |||||||||||||||||||||||||
| (In thousands, except per share data) | |||||||||||||||||||||||||
| Three Months Ended | Twelve Months Ended | ||||||||||||||||||||||||
|
December 31, |
December 31, |
||||||||||||||||||||||||
| 2010 | 2009 | 2010 | 2009 | ||||||||||||||||||||||
| (unaudited) | (note) | ||||||||||||||||||||||||
| Net income | $ | 14,972 | $ | 1,623 | $ | 21,377 | $ | 5,378 | |||||||||||||||||
|
Expenses:
Amortization of intangibles(1) |
156 |
- |
304 |
- |
|||||||||||||||||||||
| Litigation (gain)(2) | - | - | (3,529 | ) | - | ||||||||||||||||||||
| Non-cash stock-based compensation | 497 | 360 | 2,074 | 1,659 | |||||||||||||||||||||
| Income tax (benefit)(3) | (12,857 | ) | - | (12,857 | ) | - | |||||||||||||||||||
| Income tax expense(3) | 1,296 | 593 | 5,038 | 2,788 | |||||||||||||||||||||
Note: Derived from the audited financial statements at that date.
| (1) | On April 30, 2010 the Company acquired the assets related to the SmartNeedle and pdAccess products from Escalon Vascular Access, Inc. On October 20, 2010 the company acquired the assets related to the snare and retrieval product line business from Radius Medical Technologies, Inc. As part of these asset purchases, the Company allocated $6.45 million to purchased technology and other intangibles that is being amortized over a period of 9 – 10 years. | |
| (2) |
On January 22, 2010 the Company received $3.529 million as payment of the monetary judgment in a product defamation lawsuit brought by Vascular Solutions against Marine Polymer Technologies, Inc. |
|
| (3) |
Through the third quarter of 2008, the Company maintained a full valuation on its deferred tax assets. As of December 31, 2008, the Company determined that it is more likely than not that the Company would be able to realize a portion of the deferred tax assets in the future, and as a result recorded a $13.2 million income tax benefit for the year ended December 31, 2008. Thereafter, the Company began to record recurring income tax expense at estimated rates in each reporting period. As of December 31, 2010, the Company determined that it is more likely than not that the Company would be able to realize substantially all of its remaining deferred tax assets in the future, and as a result recorded a $12.9 million income tax benefit for the year ended December 31, 2010. The Company continues to assess the potential realization of its deferred tax assets on an annual basis, or an interim basis if circumstances warrant. |
|
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company’s product line consists of over 50 products in three categories: catheter products, hemostat products and vein products. Vascular Solutions delivers its products to interventional cardiologists, interventional radiologists and vascular surgeons through its direct U.S. sales force and international distributor network.
The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2009 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, lack of sustained profitability, exposure to intellectual property claims, significant variability in quarterly results, exposure to possible product liability claims, the development of new products by others, doing business in international markets, the availability of third party reimbursement, and actions by the FDA.
For further information, connect to www.vascularsolutions.com.